Companies › Herbarium Laboratorio Botanico Ltda
2 active drug programs in 2 registered trials: 1 Phase 4, 1 Phase 1; Genitourinary, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tribulus terrestris Botanical extract with putative effects on testosterone and spermatogenesis | – | Phase 4 | Oligospermia | – |
| Scar gel Topical scar treatment | – | Phase 1 | Acceptability Study | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06751433 | Scar gel | Phase 1 | Acceptability Study | Other | Dec 2025 |
| NCT06260007 | Tribulus terrestris | Phase 4 | Oligospermia | Genitourinary | Feb 2026 |
No annotated target.
–
Shanghai Bao Pharmaceuticals Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Shaanxi Micot Pharmaceutical Technology Sirnaomics Mylan Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.